WallStreetZenWallStreetZen

NASDAQ: COLL
Collegium Pharmaceutical Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Collegium Pharmaceutical earnings were $47.9M for the trailing 12 months ending Jun 30, 2026, with 33.3% growth year over year. The latest COLL earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$15.1M, down 203.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, COLL reported annual earnings of $62.9M, with -9.1% growth.

COLL past earnings growth

How has COLL's earnings growth performed historically?

Company
33.33%
Industry
100.04%
Market
91.62%
COLL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
COLL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
COLL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

COLL earnings history

Current Revenue
$808.2M
Current Earnings
$47.9M
Current Profit Margin
5.9%

COLL Return on Equity

Current Company
16%
Current Industry
1.8%
Current Market
33.4%
COLL's Return on Equity (16%)... subscribe to Premium to read more.
High Return on Equity Performance

COLL Return on Assets

Current Company
2.7%
Current Industry
3.9%
COLL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when COLL announces earnings.

COLL Return on Capital Employed

Current Company
9.97%
Current Industry
9.6%
COLL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

COLL vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
COLL$158.35M$47.92M-12.94%$1.52
GLAS-$20.41M-$52.21MN/A-$0.76
AMPH$192.86M$78.55M+51.23%$1.74
EVON/A-$281.01MN/A-$0.79
IRWD$243.64M$129.87M-24.02%$0.80
View Top Pharmaceutical Stocks

Collegium Pharmaceutical Earnings Reports & History FAQ

What were Collegium Pharmaceutical's earnings last quarter?

On COLL's earnings call on Aug 6, 2026, Collegium Pharmaceutical (NASDAQ: COLL) reported Q2 2026 earnings per share (EPS) of -$0.46, up 221.05% year over year. Total COLL earnings for the quarter were -$15.05 million. In the same quarter last year, Collegium Pharmaceutical's earnings per share (EPS) was $0.38.

If you're new to stock investing, here's how to buy Collegium Pharmaceutical stock.

Is Collegium Pharmaceutical profitable or losing money?

As of the last Collegium Pharmaceutical earnings report, Collegium Pharmaceutical is currently profitable. Collegium Pharmaceutical's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $47.92 million, a 32.1% increase year over year.

What was COLL's earnings growth in the past year?

As of Collegium Pharmaceutical's earnings date in Aug 6, 2026, Collegium Pharmaceutical's earnings has grown 33.33% year over year. This is 66.7 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 100.04%. COLL earnings in the past year totalled $47.92 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.